Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis

Chanakya Sharma, Samuel Whittle, Pari Delir Haghighi, Frada Burstein, Roee Sa'adon, Helen Isobel Keen

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Objectives: We hypothesise that patients have a positive sentiment regarding biological/targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) and a negative sentiment towards conventional synthetic agents (csDMARDs). We analysed discussions on social media platforms regarding DMARDs to understand the collective sentiment expressed towards these medications.

Methods: Treato analytics were used to download all available posts on social media about DMARDs in the context of rheumatoid arthritis. Strict filters ensured that user generated content was downloaded. The sentiment (positive or negative) expressed in these posts was analysed for each DMARD using sentiment analysis. We also analysed the reason(s) for this sentiment for each DMARD, looking specifically at efficacy and side effects. 

Results: Computer algorithms analysed millions of social media posts and included 54 742 posts about DMARDs. We found that both classes had an overall positive sentiment. The ratio of positive to negative posts was higher for b/tsDMARDs (1.210) than for csDMARDs (1.048). Efficacy was the most commonly mentioned reason in posts with a positive sentiment and lack of efficacy was the most commonly mentioned reason for a negative sentiment. These were followed by the presence/absence of side effects in negative or positive posts, respectively. 

Conclusions: Public opinion on social media is generally positive about DMARDs. Lack of efficacy followed by side effects were the most common themes in posts with a negative sentiment. There are clear reasons why a DMARD generates a positive or negative sentiment, as the sentiment analysis technology becomes more refined, targeted studies could be done to analyse these reasons and allow clinicians to tailor DMARDs to match patient needs.

Original languageEnglish
Pages (from-to)1432–1437
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume79
Issue number11
DOIs
Publication statusPublished - 2020

Keywords

  • DMARDs (biologic)
  • DMARDs (synthetic)
  • patient perspective
  • rheumatoid arthritis

Cite this